Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback